Skip to main content

Retrospective screening of microarray data to identify candidate IFN-inducible genes in a HTLV-1 transformed model

Buy Article:

$42.00 + tax (Refund Policy)

HuT-102 cells are considered one of the most representable human T-lymphotropic virus 1 (HTLV-1)-infected cell lines for studying adult Tcell lymphoma (ATL). In our previous studies, genomewide screening was performed using the GeneChip system with Human Genome Array U133 Plus 2.0 for transforming growth factorβactivated kinase 1 (TAK1), interferon regulatory factor 3 (IRF3) and IRF4regulated genes to demonstrate the effects of interferoninducible genes in HuT102 cells. Our previous findings demonstrated that TAK1 induced interferon inducible genes via an IRF3dependent pathway and that IRF4 has a counteracting effect. As our previous data was performed by manual selection of common interferonrelated genes mentioned in the literature, there has been some obscure genes that have not been considered. In an attempt to maximize the outcome of those microarrays, the present study reanalyzed the data collected in previous studies through a set of computational rules implemented using ‘R’ software, to identify important candidate genes that have been missed in the previous two studies. The final list obtained consisted of ten genes that are highly recommend as potential candidate for therapies targeting the HTLV1 infected cancer cells. Those genes are ATM, CFTR, MUC4, PARP14, QK1, UBR2, CLEC7A (Dectin1), L3MBTL, SEC24D and TMEM140. Notably, PARP14 has gained increased attention as a promising target in cancer cells.

Document Type: Research Article

Affiliations: 1: Drug Resistance Group, Centre for Cancer Research and Cell Biology, School of Medicine, Dentistry and Biomedical Science, Queen's University Belfast, Belfast BT9 7AE, Northern Ireland 2: Systems and Biomedical Engineering Department, Faculty of Engineering, Cairo University, Giza 12613, Egypt 3: Division of Pathogenic Biochemistry, Institute of Natural Medicine, Graduate School of Medical and Pharmaceutical Sciences, University of Toyama, Toyama 9300194, Japan 4: Department of Cancer Cell Biology, Graduate School of Medical and Pharmaceutical Sciences, University of Toyama, Toyama 9300194, Japan

Publication date: 01 April 2018

More about this publication?
  • Oncology Letters is a monthly, peer-reviewed journal, available in print and online, that focuses on all aspects of clinical oncology, as well as in vitro and in vivo experimental model systems relevant to the mechanisms of disease.

    The principal aim of Oncology Letters is to provide the prompt publication of original studies of high quality that pertain to clinical oncology, chemotherapy, oncogenes, carcinogenesis, metastasis, epidemiology and viral oncology in the form of original research, reviews and case reports.
  • Editorial Board
  • Information for Authors
  • Submit a Paper
  • Subscribe to this Title
  • Information for Advertisers
  • Terms & Conditions
  • Ingenta Connect is not responsible for the content or availability of external websites
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content